COMPARISON OF BUTYRYLPERAZINE AND TRLFLUOPERAZINE IN CHRONIC SCHIZOPHRENIC SUBJECTS
WILLIAM MANDEL M.D.1, and
PHILIP EVANS M.D.2
1 Chief of Research, Napa State Hospital, Napa, Calif.
2 Staff Psychiatrist, Napa State Hospital, Napa, Calif.
Butyrylperazine, a new phenothiazine of the piperazine series, was compared with trifluoperazine in a 3-month study involving 44 chronic schizophrenic patients. The study employed a double-blind, cross over design using a fixed dosage regimen of both drugs. A 2-week placebo interval was used prior to the cross over and at the completion of the study.
There were no significant differences in therapeutic effectiveness or incidence of side reactions between the drugs. Similarities between the drugs were greater than differences.
